Insulin Resistance presentations about Insulin Resistance EB with interest for Insulin Resistance Validating Insulin Resistance content Free registration form / enregistrement gratuit
1
2
   - May 12, 2008
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.

CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
  Biography  

Prof. Bart Staels

Bart Staels, PhD

Full Professor, Faculty of Pharmacie
University of Lille II
Lille, France

BIOGRAPHY
Bart Staels, PhD., is professor in the faculty of pharmacy at the University of Lille 2, Lille, France. He is also research group leader in the Department of Atherosclerosis at the Institut Pasteur de Lille, Inserm UR545, France.

Pr. Staels earned his doctorate at the Institute for Pharmaceutical Sciences, University of Leuven, Belgium. He completed postdoctoral work at the Metabolic Research Unit, University of California, San Francisco and was postdoctoral research fellow of the Reverse Cholesterol Transport/Atherosclerosis Project, BioAvenir, Vitry sur Seine, France.

Pr. Staels is a member of learned societies such as the European and International Atherosclerosis Societies, the Nouvelle Société Française d’Athérosclérose, the American Heart Association and the American Diabetes Association.

The recipient of numerous grants, awards, and scientific prizes, Pr Staels has been awarded the Young Investigator Award of the European Atherosclerosis Society, the Bronze Medal of the CNRS and the Lifetime Achievement Award of the British Atherosclerosis Society.

Pr. Staels’ research has focused on molecular pharmacology of cardiovascular and metabolic diseases. He studied particularly the role of nuclear receptors (such as the PPARs, FXR, Rev-erb and ROR in the control of inflammation and lipid and glucose homeostasis as well as the transcriptional mechanisms involved. Pr. Staels was the first to identify a crucial role for the nuclear receptor PPAR in the control of lipid and glucose metabolism as well as cardiovascular function in humans. He elucidated the action mechanism of the fibrate class of drugs that are currently used in the treatment of lipid disorders and worked also on the action mechanism of the glitazones, a very recently developped class of anti-diabetic drugs. His work has identified the PPAR transcription factors as potential drug targets for the treatment of diabetes, dyslipidemia and cardiovascular disease, which contributed to the development of several novel therapeutic compounds currently in different stages of clinical development.

To date, Pr. Staels has published more than 180 original papers and more than 100 abstracts. He has also authored 80 review articles and contributed several book chapters. Pr. Staels is also reviewer for numerous international journals and has been invited speaker at many prestigious international meetings.

 
  List of presentations from this healthcare provider available on CMEonDiabetes :

Control of Adipocyte Function by Nuclear Receptors of the PPAR and...
english - 2005-04-14 - 34 minutes
  Login
  Username :
  Password :
   
  Lost your password?


  Social
  Let others know about this biography.

 Del.icio.us
 Digg!

  Search our website
  Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes.
 
web cmeondiabetes.com




CMEonDiabetes is owned by E-MedHosting.com.


Copyright © 2002-2008 E-MedHosting.com. All rights reserved.  Disclaimer

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
insulin resistanceC-Reactive Protein (CRP)CRP, C-Reactive ProteinADHD ADDdiabetes insulin